Geode Capital Management, LLC Fibrogen Inc Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Fibrogen Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,050,637 shares of FGEN stock, worth $451,773. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,050,637

Previous 2,074,666 49.36%

Holding current value

$451,773

Previous $4.88 Million 80.82%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.89 - $2.36 $911,385 - $2.42 Million	-1,024,029 Reduced 49.36%	1,050,637 $935,000
Q1 2024 May 13, 2024	BUY	$0.73 - $2.73 $41,161 - $153,931	56,385 Added 2.79%	2,074,666 $4.88 Million
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.91 $50,665 - $121,329	133,329 Added 7.07%	2,018,281 $1.8 Million
Q3 2023 Nov 13, 2023	BUY	$0.79 - $2.83 $11,536 - $41,326	14,603 Added 0.78%	1,884,952 $1.62 Million
Q2 2023 Aug 11, 2023	BUY	$2.49 - $20.59 $355,581 - $2.94 Million	142,804 Added 8.27%	1,870,349 $5.05 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $1.12 Million - $1.77 Million	70,450 Added 4.25%	1,727,545 $32.2 Million
Q4 2022 Feb 13, 2023	BUY	$13.27 - $17.73 $690,942 - $923,165	52,068 Added 3.24%	1,657,095 $26.5 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $486,016 - $622,441	42,633 Added 2.73%	1,605,027 $20.9 Million
Q2 2022 Aug 12, 2022	SELL	$7.94 - $12.96 $183,969 - $300,283	-23,170 Reduced 1.46%	1,562,394 $16.5 Million
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $481,232 - $672,204	-40,036 Reduced 2.46%	1,585,564 $19.1 Million
Q4 2021 Feb 11, 2022	BUY	$9.93 - $15.39 $3.71 Million - $5.75 Million	373,501 Added 29.83%	1,625,600 $22.9 Million
Q3 2021 Nov 12, 2021	SELL	$10.18 - $26.64 $2.56 Million - $6.7 Million	-251,459 Reduced 16.72%	1,252,099 $12.8 Million
Q2 2021 Aug 13, 2021	BUY	$18.57 - $35.68 $1.37 Million - $2.64 Million	73,914 Added 5.17%	1,503,558 $40 Million
Q1 2021 May 12, 2021	BUY	$31.0 - $55.72 $2.82 Million - $5.07 Million	91,079 Added 6.8%	1,429,644 $49.6 Million
Q4 2020 Feb 12, 2021	BUY	$37.09 - $48.97 $2.64 Million - $3.49 Million	71,244 Added 5.62%	1,338,565 $49.6 Million
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $3,966 - $4,459	98 Added 0.01%	1,267,321 $52.1 Million
Q2 2020 Aug 13, 2020	BUY	$32.57 - $42.83 $2.28 Million - $3 Million	70,105 Added 5.86%	1,267,223 $51.4 Million
Q1 2020 May 14, 2020	BUY	$23.3 - $45.96 $1.88 Million - $3.7 Million	80,593 Added 7.22%	1,197,118 $41.6 Million
Q4 2019 Feb 13, 2020	BUY	$34.58 - $48.06 $1.65 Million - $2.3 Million	47,845 Added 4.48%	1,116,525 $47.9 Million
Q3 2019 Nov 12, 2019	BUY	$36.98 - $48.45 $1.58 Million - $2.07 Million	42,623 Added 4.15%	1,068,680 $39.5 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $2.44 Million - $3.86 Million	69,566 Added 7.27%	1,026,057 $46.4 Million
Q1 2019 May 14, 2019	BUY	$42.83 - $59.91 $3.27 Million - $4.58 Million	76,389 Added 8.68%	956,491 $52 Million
Q4 2018 Feb 13, 2019	BUY	$37.97 - $60.16 $1.91 Million - $3.03 Million	50,330 Added 6.07%	880,102 $40.7 Million
Q3 2018 Nov 13, 2018	BUY	$56.3 - $67.25 $1.09 Million - $1.3 Million	19,320 Added 2.38%	829,772 $50.4 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $4.13 Million - $5.98 Million	92,075 Added 12.82%	810,452 $50.7 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $249,062 - $338,581	-5,492 Reduced 0.76%	718,377 $33.2 Million
Q4 2017 Feb 13, 2018	BUY	$41.95 - $60.1 $96,988 - $138,951	2,312 Added 0.32%	723,869 $34.3 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $5.77 Million - $9.31 Million	172,680 Added 31.46%	721,557 $38.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	548,877	548,877 $17.7 Million

Others Institutions Holding FGEN

# of Institutions

115

Shares Held

57.5M

Call Options Held

2.14M

Put Options Held

907K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $40.3M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Fibrogen Inc Transaction History